(e,e,e,e)-squalene

(e,e,e,e)-squalene is a lipid of Fatty Acyls (FA) class. (e,e,e,e)-squalene is associated with abnormalities such as Hypercholesterolemia and Cataract. The involved functions are known as Process, metaplastic cell transformation, Protein Overexpression, Anabolism and Biosynthetic Pathways. (e,e,e,e)-squalene often locates in Membrane, Protoplasm, Plasma membrane, Tissue membrane and Back. The associated genes with (e,e,e,e)-squalene are Genome, IMPACT gene, GAPDH gene, GTF2I gene and Chromatin. The related lipids are Membrane Lipids, cycloartenol, Sterols, Fatty Acids and Nonesterified Fatty Acids.

Cross Reference

Introduction

To understand associated biological information of (e,e,e,e)-squalene, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with (e,e,e,e)-squalene?

(e,e,e,e)-squalene is suspected in Hypercholesterolemia, Cataract and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with (e,e,e,e)-squalene

MeSH term MeSH ID Detail
Nervous System Diseases D009422 37 associated lipids
Arthritis D001168 41 associated lipids
Leukemia, Experimental D007942 42 associated lipids
Occupational Diseases D009784 42 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Leukemia P388 D007941 43 associated lipids
Metabolism, Inborn Errors D008661 46 associated lipids
Coronary Artery Disease D003324 47 associated lipids
Psoriasis D011565 47 associated lipids
Precancerous Conditions D011230 48 associated lipids
Parkinson Disease D010300 53 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Pain D010146 64 associated lipids
Neuroblastoma D009447 66 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Coronary Disease D003327 70 associated lipids
Hyperlipidemias D006949 73 associated lipids
Leukemia D007938 74 associated lipids
Stomach Ulcer D013276 75 associated lipids
Alzheimer Disease D000544 76 associated lipids
Atherosclerosis D050197 85 associated lipids
Arteriosclerosis D001161 86 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Weight Gain D015430 101 associated lipids
Inflammation D007249 119 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Hemolysis D006461 131 associated lipids
Edema D004487 152 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Adenocarcinoma D000230 166 associated lipids
Lung Neoplasms D008175 171 associated lipids
Body Weight D001835 333 associated lipids
Per page 10 20 50 100 | Total 84

PubChem Associated disorders and diseases

What pathways are associated with (e,e,e,e)-squalene

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with (e,e,e,e)-squalene?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with (e,e,e,e)-squalene?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with (e,e,e,e)-squalene

Download all related citations
Per page 10 20 50 100 | Total 1766
Authors Title Published Journal PubMed Link
Li RC et al. [Study on the safety and immunogenicity of MF59-adjuvanted influenza subunit vaccine in Chinese elderly]. 2008 Zhonghua Liu Xing Bing Xue Za Zhi pmid:19040034
Liu Y et al. [Researches on influence of squalene synthase gene polymorphism on catalytic efficiency of its encode enzyme in Glycyrrhiza uralensis]. 2012 Zhongguo Zhong Yao Za Zhi pmid:23627178
de la Puerta R et al. Effect of minor components of virgin olive oil on topical antiinflammatory assays. 2000 Sep-Oct Z. Naturforsch., C, J. Biosci. pmid:11098836
Kopena R et al. Lipophilic compounds from the femoral gland secretions of male Hungarian green lizards, Lacerta viridis. 2009 May-Jun Z. Naturforsch., C, J. Biosci. pmid:19678551
Gloor M [The significance of physiological and biochemical deviations from the norm on the skin surface for infectious skin diseases (proceedings)]. 1976 Z. Hautkr. pmid:13544
Kipping D [Observations on skin surface fats]. 1965 Z Haut Geschlechtskr pmid:5860995
Sondergaard E et al. Alimentary production of gallstones in hamsters. 28. Influence of isomerized squalene on gallstone production. 1974 Z Ernahrungswiss pmid:4450595
Dam H et al. Alimentary production of gallstones in hamsters. 27. Influence of supplementation of the gallstone producing diet with squalene, cholesterol, certain other sterols, fish oil fatty acid ethyl esters, and modification of the basal diet on gallstone production and levels of cholesterol in serum and liver. 1974 Z Ernahrungswiss pmid:4615449
Zhang Y et al. [Chemical constituents from the mangrove plant Ceriops tagal]. 2005 Yao Xue Xue Bao pmid:16408813
Ikekawa T et al. [Studies on antitumor activity of squalene and its related compounds]. 1986 Yakugaku Zasshi pmid:3772729
Tsai TF MF59 adjuvanted seasonal and pandemic influenza vaccines. 2011 Yakugaku Zasshi pmid:22129867
Abe I [Engineering of squalene cyclizing enzymes]. 2008 Yakugaku Zasshi pmid:18670176
Hu JJ et al. [Antibody production and its neutralization of Abeta42's cytoxicity in BALB/c mice induced by Abeta42 and its subunit vaccines]. 2004 Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi pmid:15191720
Richter E et al. Stimulation of the faecal excretion of 2,4,5,2',4',5'-hexachlorobiphenyl in rats by squalane. 1983 Xenobiotica pmid:6415933
Global Advisory Committee on Vaccine Safety, 6-7 June 2006. 2006 Wkly. Epidemiol. Rec. pmid:16841398
Lynen F [The biochemical basis of the biosynthesis of cholesterol and fatty acids]. 1966 Wien. Klin. Wochenschr. pmid:4296920
Bakalar B et al. Changes in cholesterol and its precursors during the first days after major trauma. 2003 Wien. Klin. Wochenschr. pmid:14743581
Zhao M et al. [Research progress on the squalene synthase]. 2003 Wei Sheng Wu Xue Bao pmid:16281569
Kozlov VG and Viktorova EG [Evaluation of the efficiency and reactogenicity of emulsion-based adjuvant systems in the manufacture of polyclonal enteroviral diagnostic sera]. 2011 Mar-Apr Vopr. Virusol. pmid:21545042
Palamarchuk VI et al. [Content of squalene and sterols in tissues of the hemopoietic system in normal rats and in experimental leukemia]. 1983 May-Jun Vopr. Med. Khim. pmid:6880121
PokrovskiÄ­ AA et al. [Method of isolating, identifying and quantitatively determining alkanes, cycloalkanes, monocyclic arenes and squalene in animal organs and tissues]. 1978 Sep-Oct Vopr Pitan pmid:716335
Markelova VF and Levachev MM [Inclusion of C14-acetate in cholesterol and tissue squalene of rats in choline-protein deficiency]. 1967 Nov-Dec Vopr Pitan pmid:5610866
Gonor KV et al. [The influence of a diet with including amaranth oil on antioxidant and immune status in patients with ischemic heart disease and hyperlipoproteidemia]. 2006 Vopr Pitan pmid:17313043
Gonor KV et al. [The influence of diet with including amaranth oil on lipid metabolism in patients with ischemic heart disease and hyperlipoproteidemia]. 2006 Vopr Pitan pmid:16862949
Kulakova SN et al. [Amaranths oil: peculiarities of chemical composition and influence on lipid metabolism by rats]. 2006 Vopr Pitan pmid:16862953
Zadák Z et al. [The role of cholesterol and intermediary metabolites of its synthesis in intensive care and parenteral nutrition]. 2000 Vnitr Lek pmid:15637893
Clouse SD Brassinosteroids. Plant counterparts to animal steroid hormones? 2002 Vitam. Horm. pmid:12481548
Stephenson I et al. Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. 2004 Virus Res. pmid:15163495
Burke B et al. Neutralizing antibody responses to subtype B and C adjuvanted HIV envelope protein vaccination in rabbits. 2009 Virology pmid:19249806
Drulak MW et al. Vaccination of seropositive subjects with CHIRON CMV gB subunit vaccine combined with MF59 adjuvant for production of CMV immune globulin. 2000 Viral Immunol. pmid:10733168
Marshall BC and Adler SP Avidity maturation following immunization with two human cytomegalovirus (CMV) vaccines: a live attenuated vaccine (Towne) and a recombinant glycoprotein vaccine (gB/MF59). 2003 Viral Immunol. pmid:14733736
Heinemann L et al. Effective induction of type 1 helper IgG2a and cytotoxic T-cell responses in mice following immunization with human papillomavirus type 16 E2 in MF59. 2008 Viral Immunol. pmid:18476769
Vinay TN et al. Toxicity and dose determination of quillaja saponin, aluminum hydroxide and squalene in olive flounder (Paralichthys olivaceus). 2014 Vet. Immunol. Immunopathol. pmid:23570990
Ott G et al. Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59. 1995 Vaccine pmid:8578842
Cataldo DM and Van Nest G The adjuvant MF59 increases the immunogenicity and protective efficacy of subunit influenza vaccine in mice. 1997 Vaccine pmid:9364672
Barnett SW et al. Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit. 1997 Vaccine pmid:9234536
Hilgers LA et al. A novel non-mineral oil-based adjuvant. I. Efficacy of a synthetic sulfolipopolysaccharide in a squalane-in-water emulsion in laboratory animals. 1994 Vaccine pmid:8085385
Hilgers LA et al. A novel non-mineral oil-based adjuvant. II. Efficacy of a synthetic sulfolipopolysaccharide in a squalane-in-water emulsion in pigs. 1994 Vaccine pmid:8085386
Byars NE et al. Vaccinating guinea pigs with recombinant glycoprotein D of herpes simplex virus in an efficacious adjuvant formulation elicits protection against vaginal infection. 1994 Vaccine pmid:8165851
Barchfeld GL et al. The adjuvants MF59 and LT-K63 enhance the mucosal and systemic immunogenicity of subunit influenza vaccine administered intranasally in mice. 1999 Vaccine pmid:10067675
Dupuis M et al. Distribution of adjuvant MF59 and antigen gD2 after intramuscular injection in mice. 1999 Vaccine pmid:10519932
Heineman TC et al. A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. 1999 Vaccine pmid:10438046
De Donato S et al. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. 1999 Vaccine pmid:10462245
Stephenson I et al. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. 2003 Vaccine pmid:12639491
Iorio AM et al. Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapy. 2003 Vaccine pmid:12922092
Romera SA et al. Adjuvant effects of sulfolipo-cyclodextrin in a squalane-in-water and water-in-mineral oil emulsions for BHV-1 vaccines in cattle. 2000 Vaccine pmid:10924795
Boyce TG et al. Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults. 2000 Vaccine pmid:10930676
O'Hagan DT et al. Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1. 2000 Vaccine pmid:10699327
Süli J et al. Experimental squalene adjuvant. I. Preparation and testing of its effectiveness. 2004 Vaccine pmid:15308373
Benísek Z et al. Experimental squalene adjuvant. II. Harmlessness and local reactogenity. 2004 Vaccine pmid:15308374
Black S et al. Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis. 2010 Vaccine pmid:20813217
Cristiani C et al. Safety of MF-59 adjuvanted vaccine for pandemic influenza: results of the vaccination campaign in an Italian health district. 2011 Vaccine pmid:21396903
Meier S et al. Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children. 2011 Vaccine pmid:21419775
Parretta E et al. Italian post-marketing surveillance for adverse event reports after MF59-adjuvanted H1N1v vaccination. 2011 Vaccine pmid:21406267
Morel S et al. Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. 2011 Vaccine pmid:21256188
Decaro N et al. Immunogenicity and protective efficacy in dogs of an MF59â„¢-adjuvanted vaccine against recombinant canine/porcine coronavirus. 2011 Vaccine pmid:21272607
Calabro S et al. Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. 2011 Vaccine pmid:21215831
Javelle E et al. Delayed focal lipoatrophy after AS03-adjuvanted influenza A (H1N1) 2009 vaccine. 2011 Vaccine pmid:21172376
Esposito S et al. Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents. 2011 Vaccine pmid:21199699
Pellegrini M et al. MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. 2009 Vaccine pmid:19751689
Forrest HL et al. Single- and multiple-clade influenza A H5N1 vaccines induce cross protection in ferrets. 2009 Vaccine pmid:19406182
Keitel W et al. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial. 2010 Vaccine pmid:19835829
Vesikari T et al. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. 2009 Vaccine pmid:19840662
Ansaldi F et al. Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates. 2010 Vaccine pmid:20433807
Tsai T et al. Exposure to MF59-adjuvanted influenza vaccines during pregnancy--a retrospective analysis. 2010 Vaccine pmid:19969117
Pietrella D et al. A beta-glucan-conjugate vaccine and anti-beta-glucan antibodies are effective against murine vaginal candidiasis as assessed by a novel in vivo imaging technique. 2010 Vaccine pmid:20038431
Camilloni B et al. An influenza B outbreak during the 2007/2008 winter among appropriately immunized elderly people living in a nursing home. 2010 Vaccine pmid:20846530
Okike IO et al. The immunogenicity of a novel A (H1N1) vaccine in HIV-infected children. 2011 Vaccine pmid:21742005
Della Cioppa G et al. Trivalent and quadrivalent MF59(®)-adjuvanted influenza vaccine in young children: a dose- and schedule-finding study. 2011 Vaccine pmid:21906647
Fox CB et al. Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions. 2011 Vaccine pmid:21906648
Radosević K et al. Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants. 2008 Vaccine pmid:18514980
Brito LA et al. An alternative renewable source of squalene for use in emulsion adjuvants. 2011 Vaccine pmid:21723355
Puig-Barberà J et al. Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly. 2007 Vaccine pmid:17889411
de Bruijn I et al. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly. 2007 Vaccine pmid:18063446
Wack A et al. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. 2008 Vaccine pmid:18162266
Ansaldi F et al. Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. 2008 Vaccine pmid:18294741
de Roux A et al. Impact of corticosteroids on the immune response to a MF59-adjuvanted influenza vaccine in elderly COPD-patients. 2006 Vaccine pmid:16288937
Singh M et al. A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens. 2006 Vaccine pmid:16300864
Puig-Barberà J et al. Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age. 2004 Vaccine pmid:15530669
Del Giudice G et al. An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. 2006 Vaccine pmid:16464520
Schultze V et al. Safety of MF59 adjuvant. 2008 Vaccine pmid:18462843
Precioso AR et al. A phase I randomized, double-blind, controlled trial of 2009 influenza A (H1N1) inactivated monovalent vaccines with different adjuvant systems. 2011 Vaccine pmid:21945258
Pariani E et al. Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy. 2011 Vaccine pmid:21974995
Andrews NJ et al. Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines. 2011 Vaccine pmid:21875635
Iorio AM et al. Influenza viruses and cross-reactivity in healthy adults: humoral and cellular immunity induced by seasonal 2007/2008 influenza vaccination against vaccine antigens and 2009 A(H1N1) pandemic influenza virus. 2012 Vaccine pmid:22245606
Candela S et al. An early (3-6 weeks) active surveillance study to assess the safety of pandemic influenza vaccine Focetria in a province of Emilia-Romagna region, Italy - part one. 2013 Vaccine pmid:22766247
Langley JM et al. Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) study. 2012 Vaccine pmid:22469860
Fukase H et al. Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects. 2012 Vaccine pmid:22472791
Hatz C et al. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects. 2012 Vaccine pmid:22446638
O'Hagan DT et al. The mechanism of action of MF59 - an innately attractive adjuvant formulation. 2012 Vaccine pmid:22682289
Yu S et al. Novel Th1-biased adjuvant, SPO1, enhances mucosal and systemic immunogenicity of vaccines administered intranasally in mice. 2012 Vaccine pmid:22709954
Reynales H et al. A prospective observational safety study on MF59(®) adjuvanted cell culture-derived vaccine, Celtura(®) during the A/H1N1 (2009) influenza pandemic. 2012 Vaccine pmid:22902681
Ventura R et al. Technology transfer of an oil-in-water vaccine-adjuvant for strengthening pandemic influenza preparedness in Indonesia. 2013 Vaccine pmid:22884665
Moro ML et al. A population based cohort study to assess the safety of pandemic influenza vaccine Focetria in Emilia-Romagna region, Italy - part two. 2013 Vaccine pmid:22885015
Tetsutani K and Ishii KJ Adjuvants in influenza vaccines. 2012 Vaccine pmid:23084848
Nielsen AB et al. Immune response after one or two doses of pandemic influenza A (H1N1) monovalent, AS03-adjuvanted vaccine in HIV infected adults. 2012 Vaccine pmid:23036498
Puig-Barberà J et al. MF59-adjuvanted and virosomal influenza vaccines for preventing influenza hospitalization in older people: comparative effectiveness using the Valencia health care information system. 2013 Vaccine pmid:23731629
Van Buynder PG et al. The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly. 2013 Vaccine pmid:23933368
Vinay TN et al. Inactivated vaccine against viral hemorrhagic septicemia (VHS) emulsified with squalene and aluminum hydroxide adjuvant provides long term protection in olive flounder (Paralichthys olivaceus). 2013 Vaccine pmid:23896420
Poder A et al. An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1/2009 influenza vaccines in children 10-17 years of age. 2014 Vaccine pmid:24252703